MetLife Investment Advisors LLC lowered its position in shares of Syneos Health Inc (NASDAQ:SYNH) by 19.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 65,284 shares of the company’s stock after selling 15,689 shares during the quarter. MetLife Investment Advisors LLC owned approximately 0.06% of Syneos Health worth $2,569,000 as of its most recent filing with the SEC.
Other institutional investors and hedge funds also recently made changes to their positions in the company. Enlightenment Research LLC bought a new stake in shares of Syneos Health during the 4th quarter valued at about $51,000. NumerixS Investment Technologies Inc bought a new stake in shares of Syneos Health during the 4th quarter valued at about $57,000. Bessemer Group Inc. bought a new stake in shares of Syneos Health during the 4th quarter valued at about $59,000. Oppenheimer Asset Management Inc. bought a new stake in shares of Syneos Health during the 4th quarter valued at about $66,000. Finally, Private Capital Group LLC grew its position in shares of Syneos Health by 79.7% during the 4th quarter. Private Capital Group LLC now owns 1,824 shares of the company’s stock valued at $72,000 after buying an additional 809 shares during the last quarter.
In other news, CEO Alistair Macdonald sold 8,143 shares of the business’s stock in a transaction that occurred on Wednesday, February 13th. The shares were sold at an average price of $53.00, for a total transaction of $431,579.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. 0.44% of the stock is owned by insiders.
Syneos Health (NASDAQ:SYNH) last released its quarterly earnings results on Monday, March 18th. The company reported $0.89 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.73 by $0.16. Syneos Health had a net margin of 0.55% and a return on equity of 9.60%. The business had revenue of $1.15 billion for the quarter, compared to analyst estimates of $1.15 billion. During the same quarter in the previous year, the business earned $0.70 earnings per share. The firm’s revenue was up 6.4% compared to the same quarter last year. On average, analysts anticipate that Syneos Health Inc will post 2.72 earnings per share for the current year.
SYNH has been the subject of a number of analyst reports. Barclays reduced their target price on shares of Syneos Health from $51.00 to $45.00 and set an “equal weight” rating for the company in a research note on Thursday, January 3rd. ValuEngine lowered shares of Syneos Health from a “buy” rating to a “hold” rating in a research note on Saturday, April 13th. Robert W. Baird set a $60.00 price target on shares of Syneos Health and gave the stock a “buy” rating in a research note on Tuesday, January 8th. Credit Suisse Group upped their price target on shares of Syneos Health from $49.00 to $51.00 and gave the stock an “outperform” rating in a research note on Tuesday, March 19th. Finally, Zacks Investment Research raised shares of Syneos Health from a “hold” rating to a “buy” rating and set a $43.00 price target for the company in a research note on Tuesday, January 1st. Six investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Syneos Health currently has an average rating of “Buy” and an average target price of $53.33.
COPYRIGHT VIOLATION NOTICE: “Syneos Health Inc (SYNH) Position Lessened by MetLife Investment Advisors LLC” was originally posted by Baseball Daily News and is owned by of Baseball Daily News. If you are accessing this piece of content on another domain, it was illegally copied and reposted in violation of U.S. & international trademark and copyright law. The legal version of this piece of content can be accessed at https://www.baseballdailydigest.com/news/2019/04/21/metlife-investment-advisors-llc-reduces-holdings-in-syneos-health-inc-synh.html.
About Syneos Health
Syneos Health, Inc operates as an integrated biopharmaceutical solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers various clinical development services spanning Phase I to Phase IV, including full-service global studies, as well as unbundled service offerings, such as clinical monitoring, investigator recruitment, patient recruitment, data management, and study startup to assist customers with drug development process.
Further Reading: How do taxes affect a CDs total return?
Receive News & Ratings for Syneos Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syneos Health and related companies with MarketBeat.com's FREE daily email newsletter.